Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Public ClinicalTrials.gov record NCT00244751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to examine the safety and effectiveness of GI262570 compared to placebo (a pill that looks exactly like GI262570 but contains no active medicine) in improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who are enrolled in the study must have had prior treatment with interferon (either pegylated or standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but either failed to clear the virus or didn't tolerate the treatment.
Study identification
- NCT ID
- NCT00244751
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 265 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2, 2005 (Actual)
- Primary completion
- Mar 13, 2008 (Actual)
- Completion
- Mar 13, 2008 (Actual)
- Last update posted
- Dec 11, 2017
2005 – 2008
United States locations
- U.S. sites
- 58
- U.S. states
- 23
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294-0005 | — |
| GSK Investigational Site | Tucson | Arizona | 85719 | — |
| GSK Investigational Site | North Little Rock | Arkansas | 72117 | — |
| GSK Investigational Site | Bakersfield | California | 93301 | — |
| GSK Investigational Site | La Jolla | California | 92024 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Los Angeles | California | 90095 | — |
| GSK Investigational Site | Newport Beach | California | 92663 | — |
| GSK Investigational Site | Pasadena | California | 91105 | — |
| GSK Investigational Site | Sacramento | California | 95825 | — |
| GSK Investigational Site | San Clemente | California | 92673 | — |
| GSK Investigational Site | San Francisco | California | 94121 | — |
| GSK Investigational Site | Santa Clara | California | 95051 | — |
| GSK Investigational Site | Englewood | Colorado | 80113 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20010 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Orlando | Florida | 32804 | — |
| GSK Investigational Site | Sarasota | Florida | 34243 | — |
| GSK Investigational Site | Atlanta | Georgia | 30033 | — |
| GSK Investigational Site | Atlanta | Georgia | 30308 | — |
| GSK Investigational Site | Atlanta | Georgia | 30309 | — |
| GSK Investigational Site | Marietta | Georgia | 30060 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96817 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | Lutherville-Timonium | Maryland | 21093 | — |
| GSK Investigational Site | Boston | Massachusetts | 02111 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Boston | Massachusetts | 02215 | — |
| GSK Investigational Site | Worcester | Massachusetts | 01655 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48109 | — |
| GSK Investigational Site | Detroit | Michigan | 48202 | — |
| GSK Investigational Site | St Louis | Missouri | 63104 | — |
| GSK Investigational Site | Binghamton | New York | 13901 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10003 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | The Bronx | New York | 10468 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45219 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45267-0595 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74104 | — |
| GSK Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| GSK Investigational Site | Lancaster | Pennsylvania | 17604-3200 | — |
| GSK Investigational Site | Dallas | Texas | 75390-8887 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | San Antonio | Texas | 78215 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22908 | — |
| GSK Investigational Site | Fairfax | Virginia | 22031 | — |
| GSK Investigational Site | Richmond | Virginia | 23249 | — |
| GSK Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00244751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2017 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00244751 live on ClinicalTrials.gov.